Clozapine augmentation with amisulpride

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 6, 2014, Pages E38-E39

  Porcelli, Stefano ^a   Serretti, Alessandro ^a   Bianchini, Oriana ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; DISTRESS SYNDROME; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; JOB PERFORMANCE; MALE; META ANALYSIS (TOPIC); ORTHOSTATIC HYPOTENSION; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SOCIAL STATUS; TREATMENT REFUSAL; ANALOGS AND DERIVATIVES; DRUG POTENTIATION;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG SYNERGISM; HUMANS; MALE; SCHIZOPHRENIA; SULPIRIDE;

EID: 84908308081     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140094     Document Type: Article

References (13)

1. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996; 57(Suppl 9):35-40.
2. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
3. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012;22:165-82.
4. Taylor DM, Smith L, Gee SH, et al. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 2012;125:15-24.
5. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004;110:292-8.
6. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008;41:24-8.
7. Moller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1101-11.
8. Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009;205:119-28.
9. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004;18:933-56.
10. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
11. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res 2013;150:346-52.
12. de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl) 2013;225:1-19.
13. Giegling I, Drago A, Schafer M, et al. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010;44:487-92.